BIOD 531

Drug Profile

BIOD 531

Alternative Names: BIOD-531; Concentrated ultra-rapid-acting insulin - Albireo Pharma

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biodel
  • Developer Albireo Pharma
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 09 Mar 2016 Biodel terminates a phase II trial in Type-2 diabetes mellitus in USA due to the withdrawal of IND (NCT02446028)
  • 17 Dec 2015 Biodel suspends a phase IIa trial in Type-2 diabetes mellitus (Combination therapy) in USA (Study 3-157)
  • 03 Nov 2015 Phase-II clinical trials in Type-2 diabetes mellitus (Combination therapy) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top